Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 11/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinburnine SCHEMBL689181 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL14029339 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29771389 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL689180 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29388881 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL29391038 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL1897015 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL1897014 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL10509950 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2D6LMNANR1I2CYP1A2 | |
| Vinburnine SCHEMBL636902 | 0.89 | CYP3A4 (0.78) | CYP3A4CYP2D6LMNANR1I2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000757-A1 | COMBINATION THERAPY FOR LUNG CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2026-01-01 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4638503-A1 | COMBINATION THERAPY FOR LUNG CANCER | Bristol-Myers Squibb Company (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| EP-3749302-B1 | OXYPHENISATIN ACETATE, OXYPHENISATIN AND BISACODYL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER | US HEALTH (US) | 2024-10-23 | — | — | EP | claimed |
| US-20240316146-A1 | METHODS OF REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER | BEXION PHARMACEUTICALS INC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024137776-A1 | COMBINATION THERAPY FOR LUNG CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240019441-A1 | SETDB1-MICROTUBULE INTERACTION AND USE THEREOF | Ariel Scientific Innovations Ltd. (IL) | 2024-01-18 | — | — | US | claimed |
| EP-4284949-A1 | SETDB1-MICROTUBULE INTERACTION AND USE THEREOF | Ariel Scientific Innovations Ltd. (IL) | 2023-12-06 | — | — | EP | claimed |
| EP-4274657-A1 | METHODS OF REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER | Bexion Pharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| CN-1211164-C | Medium milling | RTP PHARMA INC (CA) | 2005-07-20 | — | — | CN | claimed |
| US-20050037068-A1 | Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs | FARMATRON LIMITED (GB) | 2005-02-17 | — | — | US | claimed |
| EP-1441705-A1 | SOLID, STABILIZED, PROMPT- AND/OR MODIFIED-RELEASE THERAPEUTICAL SYSTEMS FOR THE ORAL ADMINISTRATION OF LIQUID ACTIVE PRINCIPLES, EXCIPIENTS OR FOODSTUFFS | Farmatron Ltd. (GB) | 2004-08-04 | — | — | EP | claimed |
| CN-1441704-A | Media milling | RTP PHARMA INC (CA) | 2003-09-10 | — | — | CN | claimed |
| WO-2003039521-A1 | SOLID, STABILIZED, PROMPT- AND/OR MODIFIED-RELEASE THERAPEUTICAL SYSTEMS FOR THE ORAL ADMINISTRATION OF LIQUID ACTIVE PRINCIPLES, EXCIPIENTS OR FOODSTUFFS | FARMATRON LTD. (GB) | 2003-05-15 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0164478-B1 | CITRIC-ACID SALT OF (-)VINBURNINE AND PROCESS FOR ITS PREPARATION | COVEX (S.A.) (ES) | 1989-01-25 | — | — | EP | claimed |
| EP-0164478-A2 | Citric-acid salt of (-)vinburnine and process for its preparation | COVEX (S.A.) (ES) | 1985-12-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000757-A1 | COMBINATION THERAPY FOR LUNG CANCER | PDCD1, PDCD1LG2, CD274 | CYP3A4 4174/4885CYP2D6 2566/4885LMNA 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.